XML 68 R59.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         $ 29,621 $ 46,803
Deferred Revenue $ 27,290   $ 12,740   27,290 12,740
Related cost of goods sold         15,561 3,962
Other long-term liabilities 822   2,858   822 2,858
AstraZeneca U.S./RoW Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Accrued liabilities     11,200     11,200
Related cost of goods sold   $ 21,100        
Cumulative catch-up net adjustment   $ 25,700        
Astra Zeneca Agreements [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         159,000 89,100
Drug Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         27,673 18,753
Drug Product Revenue, Net [Member] | API Shipment [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         2,900 1,300
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         2,000 18,800
Drug Product Revenue, Net [Member] | Japan [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized       $ 14,400    
Drug Product Revenue, Net [Member] | Japan [Member] | Astellas Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         (2,872) 15,656
Accrued liabilities 2,500   1,200   2,500 1,200
Other long-term liabilities 600   700   600 700
Drug Product Revenue, Net [Member] | Europe [Member] | Astellas Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         4,874 3,097
Drug Product Revenue, Net [Member] | Europe [Member] | Astellas Europe Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Burdened manufacturing costs 600   800      
Bulk Drug Product [Member] | Astellas Europe Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred Revenue 4,400   17,700   4,400 17,700
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Drug product revenue recognized         7,200 38,700
Collaboration agreement payment         35,300  
Accrued liabilities $ 10,500   $ 38,600   10,500 38,600
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member] | Royalty Revenue [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Royalty revenue recognized as drug product revenue         $ 4,300 $ 2,300